{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:34:58Z","timestamp":1790976898373,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["24-0106"],"award-info":[{"award-number":["24-0106"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013134","name":"Office of the Assistant Secretary of Defense for Health Affairs","doi-asserted-by":"publisher","award":["W81XWH-22-1-0753"],"award-info":[{"award-number":["W81XWH-22-1-0753"]}],"id":[{"id":"10.13039\/100013134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"La Ligue Contre Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006438","name":"Office of the Assistant Secretary for Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtho.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:33:04Z","timestamp":1771590784000},"page":"103551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma"],"prefix":"10.1016","volume":"21","author":[{"given":"Gabrielle","family":"Drevet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Kalson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurane","family":"Mang\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Chalabreysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Alcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette","family":"Fernandez-Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9006-8436","authenticated-orcid":false,"given":"Matthieu","family":"Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.01.003_bib1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","volume":"43","author":"Kindler","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1513\/AnnalsATS.202209-802OC","article-title":"Global, regional, and National burden of mesothelioma 1990-2019: a systematic analysis of the global burden of disease Study 2019","volume":"20","author":"Han","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtho.2026.01.003_bib4","article-title":"Malignant pleural mesothelioma: an update","volume":"47","author":"Hajj","year":"2021","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jtho.2026.01.003_bib5","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant pleural mesothelioma: a population-based study of survival","volume":"5","author":"Milano","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.01.003_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.01.003_bib9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jtho.2025.08.009","article-title":"Molecular determinants of immunotherapy efficacy in mesothelioma: a step toward precision oncology","volume":"20","author":"Yang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-023-01816-9","article-title":"Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy","volume":"22","author":"Torricelli","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib12","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","article-title":"Single-cell view of tumor microenvironment gradients in pleural mesothelioma","volume":"14","author":"Giotti","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.01.003_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.01.003_bib14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.01.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.01.003_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtho.2026.01.003_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib20","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.01.003_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jtho.2022.05.005","article-title":"Somatic BAP1 loss as a predictive biomarker of overall survival in patients with malignant pleural mesothelioma treated with chemotherapy","volume":"17","author":"Ghafoor","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib22","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jtho.2025.06.020","article-title":"Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations","volume":"20","author":"Carbone","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib23","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.01.003_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104532","article-title":"Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma","volume":"10","author":"M\u00f6hrmann","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.01.003_bib26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.01.003_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib28","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib29","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-025-03310-0","article-title":"DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy","volume":"44","author":"Lofiego","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1158\/1078-0432.CCR-18-3683","article-title":"Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma","volume":"27","author":"Tan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/jclinpath-2016-203993","article-title":"Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma","volume":"70","author":"Alchami","year":"2017","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jtho.2026.01.003_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/modpathol.3800543","article-title":"Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases","volume":"19","author":"Ord\u00f3\u00f1ez","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.01.003_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00428-014-1664-9","article-title":"Reproducibility of histological subtyping of malignant pleural mesothelioma","volume":"465","author":"Br\u010di\u0107","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2026.01.003_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.07.015","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2026.01.003_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5858\/arpa.2018-0457-OA","article-title":"Differential diagnosis of epithelioid malignant mesothelioma with lung and breast pleural metastasis: a systematic review compared with a standardized panel of antibodies-A new proposal that may influence pathologic practice","volume":"144","author":"Le Stang","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5858\/arpa.2023-0304-RA","article-title":"Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the international mesothelioma interest group","volume":"148","author":"Husain","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/his.14783","article-title":"Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases","volume":"82","author":"Churg","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2026.01.003_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155276","article-title":"Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis","volume":"257","author":"Parra-Medina","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jtho.2026.01.003_bib41","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.01.003_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.01.003_bib44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jmoldx.2021.04.002","article-title":"DNA methylation profiling discriminates between malignant pleural mesothelioma and neoplastic or reactive histologic mimics","volume":"23","author":"Bertero","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jtho.2026.01.003_bib45","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-24-0085","article-title":"Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features","volume":"30","author":"Yang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2020.05.019","article-title":"NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer","volume":"146","author":"Leal","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103644","article-title":"Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms","volume":"9","author":"Benzerdjeb","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.01.003_bib48","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1002\/cam4.5915","article-title":"Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database","volume":"12","author":"Bou-Samra","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","article-title":"Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies","volume":"470","author":"Habougit","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2026.01.003_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2026.01.003_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib53","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib54","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1159\/000543637","article-title":"Prognostic factors in pleural mesothelioma patients receiving first-line chemotherapy: establishing the PLECH baseline risk score","volume":"103","author":"Arrieta","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.jtho.2026.01.003_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2026.01.003_bib56","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jtho.2021.06.014","article-title":"Mesothelioma risk score: a new prognostic pretreatment, clinical-molecular algorithm for malignant pleural mesothelioma","volume":"16","author":"Yeap","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib57","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/ijc.33997","article-title":"A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial","volume":"150","author":"Maille","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107287","article-title":"VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial","volume":"182","author":"Levallet","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib59","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2026.01.003_bib60","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.01.003_bib61","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from Australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2024.01.017","article-title":"Immunotherapy is a good standard option for patients with malignant pleural mesothelioma, despite the real-world results from Australia","volume":"19","author":"Smesseim","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib64","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib65","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","article-title":"VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jtho.2026.01.003_bib66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jtho.2026.01.003_bib67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13046-025-03522-4","article-title":"CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma","volume":"44","author":"Torricelli","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib68","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2025.06.018","article-title":"Immune composition and immunotherapy outcomes of mesothelioma with BAP1, CDKN2A, MTAP, and NF2 alterations","volume":"20","author":"Dagogo-Jack","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib70","article-title":"Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.01.003_bib71","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","article-title":"Niraparib plus Dostarlimab in pleural mesothelioma or non-small cell lung cancer harboring HRR mutations: interim results of the UNITO-001 Phase II prospective trial","volume":"30","author":"Passiglia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib72","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jtho.2026.01.003_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb repressor complex-2 is a novel target for mesothelioma therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.01.003_bib74","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib75","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41416-021-01547-y","article-title":"Efficacy of CDK4\/6 inhibitors in preclinical models of malignant pleural mesothelioma","volume":"125","author":"Aliagas","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib77","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.athoracsur.2021.08.054","article-title":"Inhibition of cyclin dependent kinase 4\/6 overcomes primary resistance to programmed cell death 1 blockade in malignant mesothelioma","volume":"114","author":"Jang","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2026.01.003_bib78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41698-024-00627-5","article-title":"NF2: an underestimated player in cancer metabolic reprogramming and tumor immunity","volume":"8","author":"Xu","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib79","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib80","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, Phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104481","article-title":"Unleashing precision: a review of targeted approaches in pleural mesothelioma","volume":"203","author":"Occhipinti","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2026.01.003_bib82","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41416-023-02330-x","article-title":"SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53","volume":"129","author":"Xu","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib83","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.01.003_bib84","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11912-023-01479-1","article-title":"Genomic landscape of pleural mesothelioma and therapeutic aftermaths","volume":"25","author":"Nash","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtho.2026.01.003_bib85","article-title":"A molecular phenotypic map of malignant pleural mesothelioma","volume":"12","author":"Di Genova","year":"2022","journal-title":"GigaScience"},{"key":"10.1016\/j.jtho.2026.01.003_bib86","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2021.12.004","article-title":"Discovering dominant tumor immune archetypes in a pan-cancer census","volume":"185","author":"Combes","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2026.01.003_bib87","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41568-023-00578-2","article-title":"Defining and using immune archetypes to classify and treat cancer","volume":"23","author":"Combes","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib88","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41416-018-0005-1","article-title":"Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy","volume":"118","author":"Elander","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.01.003_bib89","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib90","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtho.2024.12.014","article-title":"A perspective on the MARS2 trial","volume":"20","author":"Lim","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib91","doi-asserted-by":"crossref","first-page":"103529","DOI":"10.1016\/j.jtho.2025.11.019","article-title":"Multiomics, histologic, and scRNA-seq profiling of pleural mesothelioma reveals negative prognosis associated with a novel uncommitted molecular phenotype","volume":"21","author":"Severson","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.01.003_bib92","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.3390\/ijms23105786","article-title":"Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study","volume":"23","author":"Mannarino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2026.01.003_bib93","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.01.003_bib94","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.21037\/tcr-23-422","article-title":"A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma","volume":"12","author":"Li","year":"2023","journal-title":"Transl Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:54Z","timestamp":1778819334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1556086426000031"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.01.003","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 World Health Organization; licensee Elsevier Inc on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103551"}}